Yves Pommier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3883762/publications.pdf

Version: 2024-02-01

257 papers	29,327 citations	6250 80 h-index	5677 162 g-index
283 all docs	283 docs citations	283 times ranked	28281 citing authors

#	Article	IF	Citations
1	Topoisomerase I inhibitors: camptothecins and beyond. Nature Reviews Cancer, 2006, 6, 789-802.	12.8	1,824
2	Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Research, 2012, 72, 5588-5599.	0.4	1,657
3	DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs. Chemistry and Biology, 2010, 17, 421-433.	6.2	1,507
4	Î³H2AX and cancer. Nature Reviews Cancer, 2008, 8, 957-967.	12.8	1,423
5	A gene expression database for the molecular pharmacology of cancer. Nature Genetics, 2000, 24, 236-244.	9.4	1,357
6	Drugging Topoisomerases: Lessons and Challenges. ACS Chemical Biology, 2013, 8, 82-95.	1.6	698
7	Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nature Reviews Molecular Cell Biology, 2016, 17, 703-721.	16.1	695
8	Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib. Molecular Cancer Therapeutics, 2014, 13, 433-443.	1.9	627
9	Integrase inhibitors to treat HIV/Aids. Nature Reviews Drug Discovery, 2005, 4, 236-248.	21.5	612
10	DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition. Chemical Reviews, 2009, 109, 2894-2902.	23.0	609
11	Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene, 2004, 23, 2934-2949.	2.6	524
12	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Science Translational Medicine, 2016, 8, 362ps17.	5.8	518
13	Structures of Three Classes of Anticancer Agents Bound to the Human Topoisomerase Iâ˜'DNA Covalent Complex. Journal of Medicinal Chemistry, 2005, 48, 2336-2345.	2.9	447
14	Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nature Cell Biology, 2009, 11, 1315-1324.	4.6	445
15	A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nature Medicine, 2017, 23, 461-471.	15.2	379
16	Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nature Medicine, 2001, 7, 961-966.	15.2	339
17	Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5â€²-Phosphorylated DNA Double-Strand Breaks by Replication Runoff. Molecular and Cellular Biology, 2000, 20, 3977-3987.	1.1	314
18	Genome Organization Drives Chromosome Fragility. Cell, 2017, 170, 507-521.e18.	13.5	311

#	Article	IF	Citations
19	DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, a Potent Antitumor Compound from the Caribbean TunicateEcteinascidia turbinata. Biochemistry, 1996, 35, 13303-13309.	1.2	288
20	CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics, 2009, 10, 277.	1.2	273
21	Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair, 2014, 19, 114-129.	1.3	253
22	Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15030-15035.	3.3	252
23	Mutagenic Processing of Ribonucleotides in DNA by Yeast Topoisomerase I. Science, 2011, 332, 1561-1564.	6.0	251
24	Repair of Topoisomerase Iâ€Mediated DNA Damage. Progress in Molecular Biology and Translational Science, 2006, 81, 179-229.	1.9	247
25	The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology. Cancer Research, 2013, 73, 4372-4382.	0.4	239
26	Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 408-416.	1.3	237
27	Curcumin Analogs with Altered Potencies against HIV-1 Integrase as Probes for Biochemical Mechanisms of Drug Action. Journal of Medicinal Chemistry, 1997, 40, 3057-3063.	2.9	228
28	Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget, 2016, 7, 76534-76550.	0.8	219
29	RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription. Cell, 2016, 165, 357-371.	13.5	211
30	Ataxia telangiectasia mutated activation by transcriptionâ€•and topoisomerase Iâ€induced DNA doubleâ€strand breaks. EMBO Reports, 2009, 10, 887-893.	2.0	208
31	Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors. Cancer Investigation, 1994, 12, 530-542.	0.6	204
32	Interfacial inhibitors: targeting macromolecular complexes. Nature Reviews Drug Discovery, 2012, 11, 25-36.	21.5	204
33	Targeting Topoisomerase I in the Era of Precision Medicine. Clinical Cancer Research, 2019, 25, 6581-6589.	3.2	184
34	Topoisomerase I-mediated DNA damage. Advances in Cancer Research, 2001, 80, 189-216.	1.9	182
35	Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Research, 1990, 18, 6611-6619.	6.5	179
36	SLFN11 Blocks Stressed Replication Forks Independently of ATR. Molecular Cell, 2018, 69, 371-384.e6.	4.5	177

#	Article	IF	Citations
37	Quantitative Structure-Antitumor Activity Relationships of Camptothecin Analogues:â€‰Cluster Analysis and Genetic Algorithm-Based Studies. Journal of Medicinal Chemistry, 2001, 44, 3254-3263.	2.9	171
38	Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages. Journal of Biological Chemistry, 1999, 274, 8516-8523.	1.6	168
39	Effects of Uracil Incorporation, DNA Mismatches, and Abasic Sites on Cleavage and Religation Activities of Mammalian Topoisomerase I. Journal of Biological Chemistry, 1997, 272, 7792-7796.	1.6	164
40	PARP1â€“TDP1 coupling for the repair of topoisomerase Iâ€“induced DNA damage. Nucleic Acids Research, 2014, 42, 4435-4449.	6.5	163
41	Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends in Pharmacological Sciences, 2005, 26, 138-145.	4.0	161
42	Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resistance Updates, 1999, 2, 307-318.	6.5	158
43	Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Repairs DNA Damage Induced by Topoisomerases I and II and Base Alkylation in Vertebrate Cells. Journal of Biological Chemistry, 2012, 287, 12848-12857.	1.6	155
44	Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps. Journal of Biological Chemistry, 1997, 272, 26441-26447.	1.6	153
45	The Novel Silatecan 7-tert-Butyldimethylsilyl-10-hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity. Journal of Medicinal Chemistry, 2000, 43, 3970-3980.	2.9	147
46	Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity. Molecular Cell, 2019, 75, 252-266.e8.	4.5	145
47	The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. Molecular Cancer Therapeutics, 2009, 8, 1008-1014.	1.9	144
48	Ion Selective Folding of Loop Domains in a Potent Anti-HIV Oligonucleotideâ€. Biochemistry, 1997, 36, 12498-12505.	1.2	139
49	Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase Iâ€“DNA complexes. Journal of Cell Biology, 2011, 195, 739-749.	2.3	138
50	Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Research, 1991, 19, 5973-5980.	6.5	136
51	Production of Extrachromosomal MicroDNAs Is Linked to Mismatch Repair Pathways and Transcriptional Activity. Cell Reports, 2015, 11, 1749-1759.	2.9	135
52	Tyrosyl-DNA Phosphodiesterase as a Target for Anticancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2008, 8, 381-389.	0.9	133
53	Poly(ADP-ribose) polymerase and XPFâ€“ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Research, 2011, 39, 3607-3620.	6.5	132
54	ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses. Cancer Research, 2014, 74, 6968-6979.	0.4	131

#	Article	IF	Citations
55	MGMT Status as a Clinical Biomarker in Glioblastoma. Trends in Cancer, 2020, 6, 380-391.	3.8	131
56	Mechanisms of Camptothecin Resistance by Human Topoisomerase I Mutations. Journal of Molecular Biology, 2004, 339, 773-784.	2.0	129
57	Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK. EMBO Journal, 2009, 28, 3667-3680.	3.5	125
58	Human topoisomerases and their roles in genome stability and organization. Nature Reviews Molecular Cell Biology, 2022, 23, 407-427.	16.1	125
59	Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19790-19795.	3.3	124
60	Synthesis of Cytotoxic Indenoisoquinoline Topoisomerase I Poisons. Journal of Medicinal Chemistry, 1999, 42, 446-457.	2.9	122
61	Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget, 2016, 7, 3084-3097.	0.8	120
62	Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucleic Acids Research, 2002, 30, 1198-1204.	6.5	119
63	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. IScience, 2018, 10, 247-264.	1.9	117
64	Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response. Journal of Biological Chemistry, 2009, 284, 18085-18095.	1.6	116
65	Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel. Molecular Cancer Therapeutics, 2014, 13, 214-220.	1.9	116
66	Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase i, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. , 1999, 82, 396-404.		111
67	Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks. Cell Reports, 2019, 28, 3167-3181.e6.	2.9	108
68	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell, 2021, 39, 566-579.e7.	7.7	107
69	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. , 2019, 201, 94-102.		106
70	Proteolytic Degradation of Topoisomerase II (Top2) Enables the Processing of Top2Â·DNA and Top2Â·RNA Covalent Complexes by Tyrosyl-DNA-Phosphodiesterase 2 (TDP2). Journal of Biological Chemistry, 2014, 289, 17960-17969.	1.6	103
71	Synthesis and Mechanism of Action Studies of a Series of Norindenoisoquinoline Topoisomerase I Poisons Reveal an Inhibitor with a Flipped Orientation in the Ternary DNAâˆ'Enzymeâˆ'Inhibitor Complex As Determined by X-ray Crystallographic Analysis. Journal of Medicinal Chemistry, 2005, 48, 4803-4814.	2.9	102
72	Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity. Clinical Cancer Research, 2014, 20, 4873-4881.	3.2	102

#	Article	IF	Citations
73	Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic Analyses. Cancer Research, 2007, 67, 8752-8761.	0.4	93
74	Mitochondrial Topoisomerase I is Critical for Mitochondrial Integrity and Cellular Energy Metabolism. PLoS ONE, 2012, 7, e41094.	1.1	93
75	DNA cleavage assay for the identification of topoisomerase I inhibitors. Nature Protocols, 2008, 3, 1736-1750.	5.5	92
76	Temozolomide in the Era of Precision Medicine. Cancer Research, 2017, 77, 823-826.	0.4	91
77	SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. Clinical Cancer Research, 2015, 21, 4184-4193.	3.2	89
78	Camptothecins and Topoisomerase I; A Foot in the Door. Targeting the Genome Beyond Topoisomerase I with Camptothecins and Novel Anticancer Drugs; Importance of DNA Replication, Repair and Cell Cycle Checkpoints. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 429-434.	7.0	87
79	TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1. Nucleic Acids Research, 2012, 40, 8371-8380.	6.5	86
80	TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. Nucleic Acids Research, 2013, 41, 7793-7803.	6.5	86
81	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. Cell Reports, 2020, 33, 108296.	2.9	86
82	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Science Translational Medicine, 2020, 12, .	5.8	86
83	Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)â€“Topoisomerase I (Top1) Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 4457-4478.	2.9	85
84	Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clinical Cancer Research, 2002, 8, 2499-504.	3.2	82
85	Genomic and evolutionary classification of lung cancer in never smokers. Nature Genetics, 2021, 53, 1348-1359.	9.4	81
86	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene, 2001, 20, 1852-1859.	2.6	80
87	Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. Clinical Cancer Research, 2015, 21, 3841-3852.	3.2	80
88	Apoptosis Induced by DNA Topoisomerase I and II Inhibitors in Human Leukemic HL-60 Cells. Leukemia and Lymphoma, 1994, 15, 21-32.	0.6	78
89	Chk2 Molecular Interaction Map and Rationale for Chk2 Inhibitors: Fig. 1.. Clinical Cancer Research, 2006, 12, 2657-2661.	3.2	78
90	Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. Expert Opinion on Therapeutic Patents, 2011, 21, 1285-1292.	2.4	78

#	Article	IF	Citations
91	A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation. Science Advances, 2020, 6, .	4.7	76
92	Gene Expression Correlations in Human Cancer Cell Lines Define Molecular Interaction Networks for Epithelial Phenotype. PLoS ONE, 2014, 9, e99269.	1.1	76
93	Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. PLoS ONE, 2017, 12, e0171582.	1.1	72
94	8-Oxoguanine rearranges the active site of human topoisomerase I. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12102-12107.	3.3	68
95	Increased negative supercoiling of mtDNA in TOP1mt knockout mice and presence of topoisomerases IIÂ and IIÂ in vertebrate mitochondria. Nucleic Acids Research, 2014, 42, 7259-7267.	6.5	67
96	The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nature Cell Biology, 2022, 24, 62-73.	4.6	66
97	Interfacial Inhibitors of Protein-Nucleic Acid Interactions. Anti-Cancer Agents in Medicinal Chemistry, 2005, 5, 421-429.	7.0	65
98	Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors. Clinical Cancer Research, 2018, 24, 1944-1953.	3.2	65
99	Molecular and Biological Determinants of the Cytotoxic Actions of Camptothecins: Perspective for the Development of New Topoisomerase I Inhibitors. Annals of the New York Academy of Sciences, 2000, 922, 11-26.	1.8	64
100	RNA topoisomerase is prevalent in all domains of life and associates with polyribosomes in animals. Nucleic Acids Research, 2016, 44, 6335-6349.	6.5	63
101	Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Letters, 2001, 505, 7-12.	1.3	62
102	Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC). DNA Repair, 2020, 89, 102837.	1.3	62
103	Topoisomerase Iâ€mediated cleavage at unrepaired ribonucleotides generates DNA doubleâ€strand breaks. EMBO Journal, 2017, 36, 361-373.	3.5	59
104	Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. Molecular Cancer Therapeutics, 2021, 20, 1431-1441.	1.9	58
105	Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemotherapy and Pharmacology, 1997, 40, 433-438.	1.1	57
106	Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase in reconstituted Simian virus 40 chromatin. Nucleic Acids Research, 1990, 18, 4553-4559.	6.5	56
107	Poisoning of Mitochondrial Topoisomerase I by Lamellarin D. Molecular Pharmacology, 2014, 86, 193-199.	1.0	56
108	Hyperphosphorylation of RNA Polymerase II in Response to Topoisomerase I Cleavage Complexes and Its Association with Transcription- and BRCA1-dependent Degradation of Topoisomerase I. Journal of Molecular Biology, 2008, 381, 540-549.	2.0	55

#	Article	IF	Citations
109	Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair, 2015, 28, 107-115.	1.3	55
110	Multiview confocal super-resolution microscopy. Nature, 2021, 600, 279-284.	13.7	55
111	Biochemical Characterization of Human Tyrosyl-DNA Phosphodiesterase 2 (TDP2/TTRAP). Journal of Biological Chemistry, 2012, 287, 30842-30852.	1.6	54
112	Structural basis for recognition of 5â€²-phosphotyrosine adducts by Tdp2. Nature Structural and Molecular Biology, 2012, 19, 1372-1377.	3.6	53
113	Topoisomerase I Alone Is Sufficient to Produce Short DNA Deletions and Can Also Reverse Nicks at Ribonucleotide Sites. Journal of Biological Chemistry, 2015, 290, 14068-14076.	1.6	52
114	Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2). Journal of Medicinal Chemistry, 2016, 59, 2734-2746.	2.9	52
115	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. Journal of Thoracic Oncology, 2020, 15, 843-859.	0.5	51
116	Synthesis and Biological Evaluation of Nitrated 7-, 8-, 9-, and 10-Hydroxyindenoisoquinolines as Potential Dual Topoisomerase I (Top1)â€“Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 3188-3208.	2.9	50
117	Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11282-11287.	3.3	50
118	The NCI-60 Methylome and Its Integration into CellMiner. Cancer Research, 2017, 77, 601-612.	0.4	48
119	Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways. DNA Repair, 2020, 94, 102926.	1.3	48
120	Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress. Cell Reports, 2020, 30, 4137-4151.e6.	2.9	48
121	DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. Mutation Research DNA Repair, 1995, 337, 135-145.	3.8	47
122	DNA double-strand breaks and ATM activation by transcription-blocking DNA lesions. Cell Cycle, 2010, 9, 274-278.	1.3	47
123	A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16125-16130.	3.3	47
124	The evolving landscape of predictive biomarkers of response to PARP inhibitors. Journal of Clinical Investigation, 2018, 128, 1727-1730.	3.9	47
125	Relative contribution of four nucleases, CtIP, Dna2, Exo1 and Mre11, to the initial step of DNA doubleâ€strand break repair by homologous recombination in both the chicken DT40 and human TK6 cell lines. Genes To Cells, 2015, 20, 1059-1076.	0.5	46
126	Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 7315-7332.	2.9	44

#	Article	IF	Citations
127	Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosylâ€“DNA Phosphodiesterase 1 (Tdp1), and Tyrosylâ€“DNA Phosphodiesterase 2 (Tdp2). Journal of Medicinal Chemistry, 2017, 60, 3275-3288.	2.9	43
128	Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400). Journal of Medicinal Chemistry, 2016, 59, 4890-4899.	2.9	42
129	Structural Impact of the Leukemia Drug 1-à¥†-d-Arabinofuranosylcytosine (Ara-C) on the Covalent Human Topoisomerase I-DNA Complex. Journal of Biological Chemistry, 2003, 278, 12461-12466.	1.6	41
130	Discovery of Potent Indenoisoquinoline Topoisomerase I Poisons Lacking the 3-Nitro Toxicophore. Journal of Medicinal Chemistry, 2015, 58, 3997-4015.	2.9	40
131	Small cell lung cancer: Time to revisit DNA-damaging chemotherapy. Science Translational Medicine, 2016, 8, 346fs12.	5.8	40
132	PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes. Nucleic Acids Research, 2018, 46, 5601-5617.	6.5	40
133	BAMscale: quantification of next-generation sequencing peaks and generation of scaled coverage tracks. Epigenetics and Chromatin, 2020, 13, 21.	1.8	40
134	rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R. Bioinformatics, 2016, 32, 1272-1274.	1.8	39
135	N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. Journal of Medicinal Chemistry, 2015, 58, 4610-4623.	2.9	38
136	Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. Oncotarget, 2016, 7, 13269-13284.	0.8	38
137	Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I. Nucleic Acids Research, 2013, 41, 9848-9857.	6.5	37
138	Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. Journal of Medicinal Chemistry, 2018, 61, 9908-9930.	2.9	37
139	Different Effects on Human Topoisomerase I by Minor Groove and Intercalated Deoxyguanosine Adducts Derived from Two Polycyclic Aromatic Hydrocarbon Diol Epoxides at or Near a Normal Cleavage Site. Journal of Biological Chemistry, 2002, 277, 13666-13672.	1.6	36
140	NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clinical Cancer Research, 2018, 24, 5830-5840.	3.2	36
141	High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner. PLoS ONE, 2014, 9, e92047.	1.1	36
142	Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate. Journal of Biological Chemistry, 2000, 275, 15246-15253.	1.6	35
143	Investigation of the Structureâ€“Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons. Journal of Medicinal Chemistry, 2016, 59, 3840-3853.	2.9	35
144	HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. ACS Chemical Biology, 2016, 11, 1074-1081.	1.6	35

#	Article	IF	Citations
145	Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. Oncogene, 2019, 38, 180-193.	2.6	35
146	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repairâ€“targeted therapies. Science Translational Medicine, 2021, 13, .	5.8	35
147	Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. Nucleic Acids Research, 1999, 27, 1919-1925.	6.5	34
148	Thirteen-exon-motif signature for vertebrate nuclear and mitochondrial type IB topoisomerases. Nucleic Acids Research, 2004, 32, 2087-2092.	6.5	34
149	Interfacial inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3961-3965.	1.0	34
150	The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. Clinical Cancer Research, 2019, 25, 6206-6216.	3.2	34
151	ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair. PLoS ONE, 2017, 12, e0188320.	1.1	34
152	Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 73-81.	1.1	32
153	Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. ACS Chemical Biology, 2016, 11, 1925-1933.	1.6	32
154	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. Molecular Cancer Therapeutics, 2018, 17, 1694-1704.	1.9	30
155	SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	30
156	Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. Oncotarget, 2016, 7, 13984-14001.	0.8	30
157	Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I. Journal of Medicinal Chemistry, 2017, 60, 5364-5376.	2.9	29
158	Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. Drug Development Research, 1995, 34, 138-144.	1.4	28
159	Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. DNA Repair, 2014, 13, 1-9.	1.3	28
160	Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. Clinical Cancer Research, 2017, 23, 2116-2126.	3.2	28
161	Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome. Molecular Autism, 2018, 9, 45.	2.6	28
162	Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. Oncogene, 2020, 39, 5520-5535.	2.6	28

#	Article	IF	Citations
163	Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. Nucleic Acids Research, 2019, 47, 10134-10150.	6.5	27
164	DNA and RNA Cleavage Complexes and Repair Pathway for TOP3B RNA- and DNA-Protein Crosslinks. Cell Reports, 2020, 33, 108569.	2.9	27
165	Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. Pharmaceutical Research, 1996, 13, 1892-1895.	1.7	26
166	How Do Drug-Induced Topoisomerase I-DNA Lesions Signal to the Molecular Interaction Network that Regulates Cell Cycle Checkpoints, DNA Replication, and DNA Repair?. Cell Biochemistry and Biophysics, 2000, 33, 175-180.	0.9	26
167	PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation. Nature Communications, 2021, 12, 5010.	5.8	26
168	In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Nucleic Acids Research, 1997, 25, 4111-4116.	6.5	25
169	Mapping Topoisomerase Sites in Mitochondrial DNA with a Poisonous Mitochondrial Topoisomerase I (Top1mt). Journal of Biological Chemistry, 2014, 289, 18595-18602.	1.6	25
170	TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors. Molecular Cancer Therapeutics, 2017, 16, 2543-2551.	1.9	25
171	Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 569-579.	1.4	25
172	Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent inÂvitro anticancer activity. European Journal of Medicinal Chemistry, 2021, 215, 113261.	2.6	24
173	The dominant role of proofreading exonuclease activity of replicative polymerase Îµ in cellular tolerance to cytarabine (Ara-C). Oncotarget, 2017, 8, 33457-33474.	0.8	24
174	Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. Journal of Experimental and Clinical Cancer Research, 2016, 35, 56.	3.5	23
175	SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. Cancer Research, 2021, 81, 3067-3078.	0.4	23
176	Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. Nucleic Acids Research, 2011, 39, 6620-6632.	6.5	22
177	Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons. Bioorganic and Medicinal Chemistry, 2016, 24, 1469-1479.	1.4	22
178	Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. Frontiers in Oncology, 2019, 9, 994.	1.3	22
179	Cellular Resistance to Camptothecins. Annals of the New York Academy of Sciences, 1996, 803, 60-73.	1.8	21
180	Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. DNA Repair, 2014, 21, 177-182.	1.3	21

#	Article	IF	Citations
181	The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. BMC Cancer, 2020, 20, 1123.	1.1	21
182	Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition. Biochemical Journal, 2008, 411, 523-530.	1.7	20
183	Biological evaluation of imidazolium- and ammonium-based salts as HIV-1 integrase inhibitors. MedChemComm, 2011, 2, 143-150.	3.5	20
184	Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development. PLoS ONE, 2021, 16, e0237554.	1.1	20
185	Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes. ACS Chemical Biology, 2016, 11, 2996-3001.	1.6	19
186	Mitochondrial tyrosylâ€•<scp>DNA</scp> phosphodiesterase 2 and its <scp>TDP</scp> 2 ^S short isoform. EMBO Reports, 2018, 19, .	2.0	19
187	An interplay of NOX1-derived ROS and oxygen determines the spermatogonial stem cell self-renewal efficiency under hypoxia. Genes and Development, 2021, 35, 250-260.	2.7	19
188	Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. Cancers, 2021, 13, 4601.	1.7	19
189	Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins. Oncotarget, 2018, 9, 37286-37288.	0.8	19
190	Resolution of R-loops by topoisomerase III-Î² (TOP3B) in coordination with the DEAD-box helicase DDX5. Cell Reports, 2022, 40, 111067.	2.9	19
191	Biochemical Assays for the Discovery of TDP1 Inhibitors. Molecular Cancer Therapeutics, 2014, 13, 2116-2126.	1.9	18
192	Chromatin Regulators as a Guide for Cancer Treatment Choice. Molecular Cancer Therapeutics, 2016, 15, 1768-1777.	1.9	18
193	DNA-Targeted Precision Medicine; Have We Been Caught Sleeping?. Trends in Cancer, 2017, 3, 2-6.	3.8	18
194	Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites. Chemical Science, 2021, 12, 3876-3884.	3.7	18
195	A polymer index-matched to water enables diverse applications in fluorescence microscopy. Lab on A Chip, 2021, 21, 1549-1562.	3.1	18
196	Novel TDP2-ubiquitin interactions and their importance for the repair of topoisomerase II-mediated DNA damage. Nucleic Acids Research, 2016, 44, gkw719.	6.5	17
197	Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription. Journal of Biological Chemistry, 2017, 292, 20162-20172.	1.6	17
198	Structural, molecular, and functional insights into Schlafen proteins. Experimental and Molecular Medicine, 2022, 54, 730-738.	3.2	17

#	Article	IF	Citations
199	Neuroprotection and repair of 3'-blocking DNA ends by glaikit (glk) encoding Drosophila tyrosyl-DNA phosphodiesterase 1 (TDP1). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15816-15820.	3.3	16
200	Selectivity for strand-transfer over 3â€²-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzymeâ€“DNA interactions in the active site. Nucleic Acids Research, 2016, 44, 6896-6906.	6.5	16
201	Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14412-14420.	3.3	16
202	Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1â€“DNA complexes. Nucleic Acids Research, 2021, 49, 10493-10506.	6.5	16
203	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. International Journal of Cancer, 1994, 58, 85-94.	2.3	15
204	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. Marine Drugs, 2015, 13, 3625-3639.	2.2	15
205	Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors. European Journal of Medicinal Chemistry, 2015, 101, 525-533.	2.6	15
206	Parallel analysis of ribonucleotide-dependent deletions produced by yeast Top1in vitroandin vivo. Nucleic Acids Research, 2016, 44, 7714-7721.	6.5	15
207	TDP1 suppresses mis-joining of radiomimetic DNA double-strand breaks and cooperates with Artemis to promote optimal nonhomologous end joining. Nucleic Acids Research, 2018, 46, 8926-8939.	6.5	15
208	Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. DNA Repair, 2020, 85, 102747.	1.3	15
209	2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 355-378.	2.5	15
210	Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. International Journal of Cancer, 1995, 63, 268-275.	2.3	14
211	New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2). European Journal of Pharmaceutical Sciences, 2018, 118, 67-79.	1.9	14
212	Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) Series. Journal of Medicinal Chemistry, 2018, 61, 10440-10462.	2.9	14
213	Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer. Journal of Medicinal Chemistry, 2021, 64, 7617-7629.	2.9	14
214	Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors. Molecular Cancer Therapeutics, 2015, 14, 2552-2559.	1.9	13
215	HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia. Scientific Reports, 2017, 7, 12849.	1.6	13
216	Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides. European Journal of Pharmaceutical Sciences, 2018, 111, 337-348.	1.9	13

#	Article	IF	Citations
217	Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide. Journal of Medicinal Chemistry, 2019, 62, 4669-4682.	2.9	13
218	TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular Cancer Therapeutics, 2022, 21, 1090-1102.	1.9	13
219	Distribution bias and biochemical characterization of TOP1MT single nucleotide variants. Scientific Reports, 2017, 7, 8614.	1.6	12
220	Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1). SLAS Discovery, 2017, 22, 1093-1105.	1.4	12
221	Endogenous single-strand DNA breaks at RNA polymerase II promoters in Saccharomyces cerevisiae. Nucleic Acids Research, 2018, 46, 10649-10668.	6.5	12
222	Replication Stress Defines Distinct Molecular Subtypes Across Cancers. Cancer Research Communications, 2022, 2, 503-517.	0.7	12
223	Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. Cancer Chemotherapy and Pharmacology, 2000, 45, 409-416.	1.1	11
224	Beyond the unwinding: role of TOP1MT in mitochondrial translation. Cell Cycle, 2019, 18, 2377-2384.	1.3	11
225	Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. European Journal of Medicinal Chemistry, 2019, 178, 81-92.	2.6	11
226	Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states. Nature Communications, 2022, 13, 59.	5.8	11
227	Anti-HIV-1 activity of a tripodal receptor that recognizes mannose oligomers. European Journal of Medicinal Chemistry, 2015, 106, 132-143.	2.6	10
228	F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. Future Oncology, 2016, 12, 2183-2188.	1.1	10
229	The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2. Molecular Cancer Therapeutics, 2020, 19, 1589-1597.	1.9	10
230	Early Induction of Apoptosis in Hematopoietic Cell Lines After Exposure to Flavopiridol. Blood, 1998, 91, 458-465.	0.6	10
231	Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinumâ€based chemotherapy. Cancer Science, 2022, 113, 784-795.	1.7	10
232	Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae. DNA Repair, 2017, 59, 69-75.	1.3	9
233	Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor. Molecular Cancer Research, 2021, 19, 1338-1349.	1.5	9
234	DNA Topoisomerases and Their Inhibition by Anthracyclines. ACS Symposium Series, 1994, , 183-203.	0.5	8

#	Article	IF	Citations
235	Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I. Journal of the American Chemical Society, 2020, 142, 21178-21188.	6.6	7
236	SUMO: A Swiss Army Knife for Eukaryotic Topoisomerases. Frontiers in Molecular Biosciences, 2022, 9, 871161.	1.6	7
237	Virtual screening using ligand-based pharmacophores for inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1). Bioorganic and Medicinal Chemistry, 2010, 18, 2347-2355.	1.4	6
238	Mammalian Tyrosyl-DNA Phosphodiesterases in the Context of Mitochondrial DNA Repair. International Journal of Molecular Sciences, 2019, 20, 3015.	1.8	6
239	Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes. Science Advances, 2021, 7, .	4.7	6
240	Schlafen 11 Expression in Human Acute Leukemia Cells with Gain-of-Function Mutations in the Interferon-JAK Signaling Pathway. IScience, 2021, 24, 103173.	1.9	6
241	Mutations in the HIV Type 1 Integrase of Patients Receiving Long-Term Dideoxynucleoside Therapy Do Not Confer Resistance to Zidovudine. AIDS Research and Human Retroviruses, 2000, 16, 1417-1422.	0.5	5
242	topIb, a phylogenetic hallmark gene of Thaumarchaeota encodes a functional eukaryote-like topoisomerase IB. Nucleic Acids Research, 2016, 44, 2795-2805.	6.5	5
243	Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening. Molecules, 2019, 24, 3675.	1.7	5
244	The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 818-822.	2.5	5
245	Design and synthesis of C-aryl angular luotonins via a one-pot aza-Nazarovâ€“Friedlander sequence and their Topo-I inhibition studies along with C-aryl vasicinones and luotonins. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 127998.	1.0	5
246	From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge Dendrilla antarctica. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1404-1410.	2.5	5
247	Probing the evolutionary conserved residues Y204, F259, S400 and W590 that shape the catalytic groove of human TDP1 for 3â€²- and 5â€²-phosphodiester-DNA bond cleavage. DNA Repair, 2018, 66-67, 64-71.	1.3	4
248	Synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as tyrosyl-DNA phosphodiesterase 1 inhibitors and their anticancer activity. Bioorganic Chemistry, 2022, 123, 105789.	2.0	4
249	HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence. Molecules, 2018, 23, 1858.	1.7	3
250	Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1. Cancer Research, 2019, 79, 2460-2461.	0.4	3
251	CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II. Molecular Cancer Therapeutics, 2022, 21, 1430-1438.	1.9	3
252	Novel screen for anti-cancer drugs that elevate chromosome instability (CIN) using human artificial chromosome (HAC). Oncotarget, 2018, 9, 36833-36835.	0.8	2

#	Article	IF	Citations
253	Cancer/Testis Antigen 55 is required for cancer cell proliferation and mitochondrial DNA maintenance. Mitochondrion, 2022, 64, 19-26.	1.6	2
254	Bay-Region Diol Epoxides of Benzo[a]Pyrene are Stealth Poisons of Topoisomerase I. Polycyclic Aromatic Compounds, 2000, 21, 53-62.	1.4	0
255	Response to Letter to the Editor by Yang etÂal.. Journal of Thoracic Oncology, 2020, 15, e91.	0.5	0
256	Functions of the CSB Protein at Topoisomerase 2 Inhibitors-Induced DNA Lesions. Frontiers in Cell and Developmental Biology, 2021, 9, 727836.	1.8	0
257	Topoisomeraseâ€Induced DNA Cleavage at Ribonucleotide Misincorporation Sites. FASEB Journal, 2015, 29, 371.3.	0.2	0